Trasylol Re-Examination To Follow After Bayer Halts Enrollment In BART Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Enrollment in the blood conservation study was stopped due to an increase in mortality in patients receiving aprotinin injection.
You may also be interested in...
BART Sends Bayer’s Trasylol Off The Market
Bayer “temporarily” phases out proteinase inhibitor after top-line data show 50% higher death rate for Trasylol versus comparators.
BART Sends Bayer’s Trasylol Off The Market
Bayer “temporarily” phases out proteinase inhibitor after top-line data show 50% higher death rate for Trasylol versus comparators.
Joint Panel Favors More Postmarketing Studies For Bayer’s Trasylol
Despite the unanimous recommendation for additional pharmacovigilance for safety, the cardio-renal and drug safety committees vote against taking the product off the market.